Analysts project the market could expand fivefold within five years
FDA-approved GLP-1 weight loss medications available at Vitercure Wegovy (semaglutide 2.4mg weekly) for chronic weight management Zepbound (tirzepatide weekly) for chronic weight management and sleep apnea Ozempic (semaglutide weekly) for type 2 diabetes management Mounjaro (tirzepatide weekly) for type 2 diabetes management Saxenda (liraglutide 3mg daily) for chronic weight management Rybelsus (oral semaglutide) for type 2 diabetes management Trulicity (dulaglutide weekly) for type 2 diabetes management For a head-to-head comparison, see our guide on Wegovy vs Zepbound vs Mounjaro vs Saxenda
Potential Benefits and Clinical Outcomes Using GLP-1 receptor agonists as an add-on therapy in type 1 diabetes offers several potential advantages, especially for patients with complex metabolic needs
Clinical evidence consistently demonstrates that patients regain approximately one-third of lost weight within the first year of stopping GLP-1 therapy, with longer-term studies suggesting even more substantial rebound [50]
Analysis of the Rehmannia chingii geneome identifies RcCYP72H7 as an epoxidase in iridoid glycoside biosynthesis
Common allergens include pollen, cats, dust mites, nuts, dairy, and fish
